Hexagon Bio, a biopharmaceutical company pioneering the discovery of novel payload mechanisms for antibody-drug conjugates (ADCs), announced the closing of a $62 million Series C financing. The round was led by The Column Group, with participation from existing investors including Nextech Invest, Deviation Capital, 8VC, and Canada Pension Plan Investment Board (CPP Investments).